RANKL/RANK is required for cytokine-induced beta cell death; osteoprotegerin, a RANKL inhibitor, reverses rodent type 1 diabetes

Treatment for type 1 diabetes (T1D) requires stimulation of functional β cell regeneration and survival under stress. Previously, we showed that inhibition of the RANKL/RANK [receptor activator of nuclear factor kappa Β (NF-κB) ligand] pathway, by osteoprotegerin and the anti-osteoporotic drug denos...

Descripción completa

Detalles Bibliográficos
Autores principales: Kondegowda, Nagesha Guthalu, Filipowska, Joanna, Do, Jeong-su, Leon-Rivera, Nancy, Li, Rosemary, Hampton, Rollie, Ogyaadu, Selassie, Levister, Camilla, Penninger, Josef M., Reijonen, Helena, Levy, Carol J., Vasavada, Rupangi C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2023
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619938/
https://www.ncbi.nlm.nih.gov/pubmed/37910614
http://dx.doi.org/10.1126/sciadv.adf5238

Ejemplares similares

Ejemplares similares